These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 28315359)
21. Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. Klussman K; Mixan BJ; Cerveny CG; Meyer DL; Senter PD; Wahl AF Bioconjug Chem; 2004; 15(4):765-73. PubMed ID: 15264863 [TBL] [Abstract][Full Text] [Related]
22. The role of therapeutic antibodies in drug discovery. Stockwin LH; Holmes S Biochem Soc Trans; 2003 Apr; 31(2):433-6. PubMed ID: 12653655 [TBL] [Abstract][Full Text] [Related]
23. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. Niwa R; Satoh M J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555 [TBL] [Abstract][Full Text] [Related]
24. Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy? Sousa F; Castro P; Fonte P; Kennedy PJ; Neves-Petersen MT; Sarmento B Expert Opin Drug Deliv; 2017 Oct; 14(10):1163-1176. PubMed ID: 28005451 [TBL] [Abstract][Full Text] [Related]
25. Controlled antibody/(bio-) conjugation of inorganic nanoparticles for targeted delivery. Montenegro JM; Grazu V; Sukhanova A; Agarwal S; de la Fuente JM; Nabiev I; Greiner A; Parak WJ Adv Drug Deliv Rev; 2013 May; 65(5):677-88. PubMed ID: 23280372 [TBL] [Abstract][Full Text] [Related]
26. The state-of-play and future of antibody therapeutics. Elgundi Z; Reslan M; Cruz E; Sifniotis V; Kayser V Adv Drug Deliv Rev; 2017 Dec; 122():2-19. PubMed ID: 27916504 [TBL] [Abstract][Full Text] [Related]
28. The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics. Qian L; Lin X; Gao X; Khan RU; Liao JY; Du S; Ge J; Zeng S; Yao SQ Chem Rev; 2023 Jun; 123(12):7782-7853. PubMed ID: 37186942 [TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody therapy for malignant glioma. Chen KS; Mitchell DA Adv Exp Med Biol; 2012; 746():121-41. PubMed ID: 22639164 [TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies: technologies for early discovery and engineering. Kennedy PJ; Oliveira C; Granja PL; Sarmento B Crit Rev Biotechnol; 2018 May; 38(3):394-408. PubMed ID: 28789584 [TBL] [Abstract][Full Text] [Related]
31. Emerging formats for next-generation antibody drug conjugates. Deonarain MP; Yahioglu G; Stamati I; Marklew J Expert Opin Drug Discov; 2015 May; 10(5):463-81. PubMed ID: 25797303 [TBL] [Abstract][Full Text] [Related]
32. Molecular platforms for targeted drug delivery. Maso K; Grigoletto A; Vicent MJ; Pasut G Int Rev Cell Mol Biol; 2019; 346():1-50. PubMed ID: 31122392 [TBL] [Abstract][Full Text] [Related]
33. Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives. Zangemeister-Wittke U Pathobiology; 2005; 72(6):279-86. PubMed ID: 16582579 [TBL] [Abstract][Full Text] [Related]
34. Antibody-cytotoxic agent conjugates for cancer therapy. Chen J; Jaracz S; Zhao X; Chen S; Ojima I Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784 [TBL] [Abstract][Full Text] [Related]
35. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment. Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588 [TBL] [Abstract][Full Text] [Related]